Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 1/15/26 | Compass Therapeutics (CMPX) | tovecimig for Biliary Tract Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/8/26 | Eli Lilly (LLY) | Mounjaro for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/8/26 | Eli Lilly (LLY) | Taltz for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/8/26 | Ascendis Pharma (ASND) | TransCon CNP for Achondroplasia | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/7/26 | Praxis (PRAX) | relutrigine for Seizure Disorders (Epilepsy) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/30/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Patient Enrollment Completed |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |